Skip to main content
. 2021 Apr 2;7(14):eabd1453. doi: 10.1126/sciadv.abd1453

Fig. 4. Agonist ChemR23 mAb accelerates the resolution of acute colon inflammation.

Fig. 4

(A) Weight variation, (B) colon length (d22), and (C) diarrhea (stool score) of mice in the acute DSS (2%) colitis model treated intraperitoneally at d0, d2, and d4 with isotype hIgG1 (black; n = 10) or anti-ChemR23 (blue; n = 10) mAb at 1 mg/kg or RvE1 (50 μg/kg per day; gray; n = 10) daily for 5 days. (D) Resolution index of colitis based on the time to resolve 50% of the diarrhea symptoms as discussed in (90). (E) Weight variation and (F) colon length (d5) of mice in the acute intrarectal TNBS/ethanol (50%) colitis model treated intraperitoneally at d0 and d2 with isotype (control) or anti-ChemR23 mAbs (1 mg/kg) or RvE1 (50 μg/kg per day) daily for 3 days(n = 9 to 10 per group). Naïve, age-matched mice that did not receive administration of DSS or TNBS/ethanol. *P < 0.05 and **P < 0.01 (Mann-Whitney).